HOME >> MEDICINE >> NEWS
GroPep completes final milestone of the path malaria vaccine initiative

Adelaide biotechnology company GroPep has completed the manufacture of two vaccine antigens as part of the project funded by the international PATH Malaria Vaccine Initiative (MVI).

GroPep will supply these vaccine antigens to the MVI for formulation and subsequent use in human clinical trials - expected to start in 2007.

Listed biopharmaceutical company GroPep Limited (ASX :GRO) announced today that it had successfully completed the second and final milestone of its agreement with the PATH Malaria Vaccine Initiative to manufacture malaria vaccine candidates for testing in human clinical trials.

GroPep reported the successful completion to Milestone 1 of the vaccine project in September 2003, developing scalable manufacturing processes for two malaria vaccine candidates.

Milestone 2 required scale-up of production and manufacturing to appropriate quality standards to enable the potential malaria vaccines to be tested in human safety trials. A sufficient quantity of each vaccine antigen has been manufactured.

PATH is an international, non-profit organisation that creates sustainable, culturally relevant solutions allowing global communities to break long-standing cycles of poor health. The Malaria Vaccine Initiative's (MVI) mission is to accelerate the development of malarial vaccines for the developing world. Malaria kills 7000 people each week and there is no vaccine.

MVI Director, Dr Melinda Moree congratulated GroPep on completing this important project milestone. "GroPep has made an important contribution to the quest to develop a vaccine against malaria."

GroPep's CEO, Bob Finder said that the manufacturing project had provided GroPep with a number of technical challenges that had been successfully met.

"As a Company, we are pleased to have successfully completed our part of the project, which may ultimately reduce the impact of this disease on millions of people worldwide," he said.
'"/>

Contact: Tony Mitchell
investorrelations@gropep.com.au
61-883-547-700
Research Australia
19-Dec-2005


Page: 1 2

Related medicine news :

1. GroPep awarded key patent for infertility treatment in Europe
2. GroPep starts Phase 1 infertility trial
3. GroPep to pursue promising asthma drug following preclinical study results
4. GroPep licenses technology to TGR BioSciences
5. GroPep news: Key psoriasis patent granted in Japan and new asthma patent filed for GroPep drug
6. Asthmatx completes enrollment in pivotal study of bronchial thermoplasty
7. Acrux completes enrollment in key phase 2 trial
8. MacroChem completes patient enrollment for Phase II trial of EcoNail for treatment of onychomycosis
9. Im a Kid Too project completes first phase
10. 6 finalists compete for achievement in operations research
11. Heart Rhythm Society publishes final recommendations for heart patients

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/10/2019)... Tenn. (PRWEB) , ... October 10, 2019 , ... ... of management consulting and information technology (IT) services for the healthcare industry, has ... the Public Hospitals Authority (PHA) of the Commonwealth of The Bahamas towards a ...
(Date:10/8/2019)... ... October 08, 2019 , ... What unique insights can ... state of aging and wellness in the nation? That question will be answered at ... Conference, Leadership Summit and Expo. The event will take place October 10-12, 2019, at ...
(Date:10/8/2019)... ... October 08, 2019 , ... ... for the Department of Veterans Affairs Community Care Referrals and Authorizations program. The ... the VA’s Health Share Referral Manager (HSRM), an enterprise-wide system used by community ...
(Date:10/8/2019)... ... ... Over the past three decades, Buffalo Wings & Rings has elevated the chicken wing ... higher-quality product and experience than the competition. Now, the club-level sports restaurant brand has ... THE CAUSE" campaign in support of Breast Cancer Awareness Month. , “We are ...
(Date:10/8/2019)... ... October 08, 2019 , ... The University of California San ... Awards 1st Round (Top Ten) Finalist in its Best Cardiovascular Digital Diagnostic category. ... promote faster, better, more cost-effective healthcare by improving outcomes such as shorter hospital ...
Breaking Medicine News(10 mins):
(Date:10/22/2019)... , ... October 22, 2019 , ... ... the 2019 Excellency in Advocacy Award for Excellence in a State Issue Campaign ... initiative, SUNucate , and the contributions of ASDSA’s Advocacy team: Kristin Hellquist, ...
(Date:10/19/2019)... ... October 18, 2019 , ... Whealthcare Planning, the industry’s only ... growing momentum for the company and its technology, along and a corresponding capital ... wealthmanagement.com’s Industry Awards Program, Whealthcare Planning was recognized for Technology Thought Leadership for ...
(Date:10/19/2019)... ... ... Hospital M&A activity held steady with 21 transactions in both the second ... recent quarter was down 20% compared with the same period in 2018, when 25 ... nearly $5.0 billion, a 291% increase. Year over year, Q3:19 spending was down 41% ...
Breaking Medicine Technology:
Cached News: